Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
dc.contributor.author | Moreno, V. | |
dc.contributor.author | Barretina-Ginesta, M. P. | |
dc.contributor.author | García-Donas, J. | |
dc.contributor.author | Jayson, Gordon C | |
dc.contributor.author | Roxburgh, P. | |
dc.contributor.author | Vázquez, R. M. | |
dc.contributor.author | Michael, A. | |
dc.contributor.author | Antón-Torres, A. | |
dc.contributor.author | Brown, R. | |
dc.contributor.author | Krige, D. | |
dc.contributor.author | Champion, B. | |
dc.contributor.author | McNeish, I. | |
dc.date.accessioned | 2022-01-11T12:00:08Z | |
dc.date.available | 2022-01-11T12:00:08Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Moreno V, Barretina-Ginesta M-P, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial Vol. 9, Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. e003645. | en |
dc.identifier.pmid | 34893524 | en |
dc.identifier.doi | 10.1136/jitc-2021-003645 | en |
dc.identifier.uri | http://hdl.handle.net/10541/624962 | |
dc.title | Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial | en |
dc.type | Article | en |
dc.contributor.department | START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain | en |
dc.identifier.journal | Journal for Immunotherapy of Cancer | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-04-12T10:12:56Z |